CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
Diagnovus has launched Engauge-cancer-DLBCL, a commercial gene-expression assay for risk stratification and treatment of patients with diffuse large B-cell lymphoma.
“Engauge-cancer-DLBCL, which combines a patient’s IPI [International Prognostic Index] score and the results of the gene-expression assay, can more accurately predict outcomes for patients than IPI alone in order to optimize treatment choices for patients,” Ron Levy, MD, leader of the Lymphoma Program at Stanford University School of Medicine, said in a statement. “Traditional stratification schemes based on clinical characteristics such as the IPI have provided prognostic guidance in the management of patients with DLBCL. Despite the ease of use, IPI does not fully capture disease heterogeneity, and it is common to have two patients with identical IPI risk scores have very different outcomes.”
James Stover, PhD, VP and co-founder of Diagnovus, says the Engauge-cancer-DLBCL assay is the first of a line of molecular diagnostic tests for less frequent diseases.
“Using well-studied genes incorporated into a multiplexed panel, Engauge-cancer-DLBCL has been developed from more than 10 years of research and exceeds the standard clinical characteristics that clinicians have used for prognosis for the last three decades,” Dr. Stover said in a statement. “Even more important is the fact that we can perform this assay in a reproducible and accurate manner using routinely available formalin-fixed paraffin-embedded diagnostic biopsy tissue, unlike other genome-based assays that require special handling, such as snap freezing in liquid nitrogen.”
Diagnovus, 855-642-8438